Mark Pollack to Combined Modality Therapy
This is a "connection" page, showing publications Mark Pollack has written about Combined Modality Therapy.
Connection Strength
1.836
-
Changes in Dosing and Dose Timing of D-Cycloserine Explain Its Apparent Declining Efficacy for Augmenting Exposure Therapy for Anxiety-related Disorders: An Individual Participant-data Meta-analysis. J Anxiety Disord. 2019 12; 68:102149.
Score: 0.166
-
Enhancement of Psychosocial Treatment With D-Cycloserine: Models, Moderators, and Future Directions. Biol Psychiatry. 2016 08 15; 80(4):274-283.
Score: 0.126
-
Dose timing of D-cycloserine to augment cognitive behavioral therapy for social anxiety: Study design and rationale. Contemp Clin Trials. 2015 Jul; 43:223-30.
Score: 0.124
-
D-cycloserine augmentation of cognitive behavioral therapy for anxiety disorders: an update. Curr Psychiatry Rep. 2015 Jan; 17(1):532.
Score: 0.120
-
Sleep quality predicts treatment outcome in CBT for social anxiety disorder. Depress Anxiety. 2013 Nov; 30(11):1114-20.
Score: 0.109
-
D-cycloserine augmentation of cognitive behavioral group therapy of social anxiety disorder: prognostic and prescriptive variables. J Consult Clin Psychol. 2013 Dec; 81(6):1100-12.
Score: 0.109
-
D-Cycloserine as an augmentation strategy with cognitive-behavioral therapy for social anxiety disorder. Am J Psychiatry. 2013 Jul; 170(7):751-8.
Score: 0.108
-
Next-step strategies for panic disorder refractory to initial pharmacotherapy: a 3-phase randomized clinical trial. J Clin Psychiatry. 2009 Nov; 70(11):1563-70.
Score: 0.083
-
Paroxetine CR augmentation for posttraumatic stress disorder refractory to prolonged exposure therapy. J Clin Psychiatry. 2008 Mar; 69(3):400-5.
Score: 0.075
-
Novel treatment approaches for refractory anxiety disorders. Depress Anxiety. 2008; 25(6):467-76.
Score: 0.074
-
Long-term management of panic disorder. J Clin Psychiatry. 2004; 65 Suppl 5:24-8.
Score: 0.056
-
Treatment of pharmacotherapy-refractory posttraumatic stress disorder among Cambodian refugees: a pilot study of combination treatment with cognitive-behavior therapy vs sertraline alone. Behav Res Ther. 2003 Nov; 41(11):1271-6.
Score: 0.055
-
WCA recommendations for the long-term treatment of panic disorder. CNS Spectr. 2003 Aug; 8(8 Suppl 1):17-30.
Score: 0.054
-
Using pre-treatment de novo threat conditioning outcomes to predict treatment response to DCS augmentation of exposure-based CBT. J Psychiatr Res. 2023 08; 164:357-363.
Score: 0.054
-
Antibacterial properties of Pseudomonas aeruginosa immunotype 1 lipopolysaccharide-specific monoclonal antibody (MAb) in a murine thigh infection model: combined effects of MAb and ceftazidime. Microbiol Immunol. 2000; 44(8):629-35.
Score: 0.042
-
Social anxiety disorder: designing a pharmacologic treatment strategy. J Clin Psychiatry. 1999; 60 Suppl 9:20-6.
Score: 0.040
-
Rate of improvement during cognitive-behavioral group treatment for panic disorder. Behav Res Ther. 1998 Jul-Aug; 36(7-8):665-73.
Score: 0.038
-
Does d-cycloserine facilitate the effects of homework compliance on social anxiety symptom reduction? J Anxiety Disord. 2018 01; 53:85-90.
Score: 0.037
-
D-Cycloserine Augmentation of Exposure-Based Cognitive Behavior Therapy for Anxiety, Obsessive-Compulsive, and Posttraumatic Stress Disorders: A Systematic Review and Meta-analysis of Individual Participant Data. JAMA Psychiatry. 2017 05 01; 74(5):501-510.
Score: 0.035
-
RANDOMIZED TRIAL OF D-CYCLOSERINE ENHANCEMENT OF COGNITIVE-BEHAVIORAL THERAPY FOR PANIC DISORDER. Depress Anxiety. 2016 08; 33(8):737-45.
Score: 0.033
-
The desire to belong: Social identification as a predictor of treatment outcome in social anxiety disorder. Behav Res Ther. 2016 06; 81:21-34.
Score: 0.033
-
The longitudinal course and outcome of panic disorder. Psychiatr Clin North Am. 1995 Dec; 18(4):785-801.
Score: 0.032
-
Integrated treatment of panic disorder. Bull Menninger Clin. 1995; 59(2 Suppl A):A4-26.
Score: 0.030
-
Cognitive behavior therapy for treatment-refractory panic disorder. J Clin Psychiatry. 1994 May; 55(5):200-5.
Score: 0.029
-
Randomized controlled trial of mindfulness meditation for generalized anxiety disorder: effects on anxiety and stress reactivity. J Clin Psychiatry. 2013 Aug; 74(8):786-92.
Score: 0.027
-
Cocaine abuse and treatment. Compr Psychiatry. 1989 Jan-Feb; 30(1):31-44.
Score: 0.020
-
A pilot study of vagus nerve stimulation (VNS) for treatment-resistant anxiety disorders. Brain Stimul. 2008 Apr; 1(2):112-21.
Score: 0.019
-
Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. Arch Gen Psychiatry. 2006 Mar; 63(3):298-304.
Score: 0.016
-
Discussion: using benzodiazepines in clinical practice. J Clin Psychiatry. 2005; 66 Suppl 2:39-43; quiz 44-5.
Score: 0.015
-
WCA Recommendations for the long-term treatment of posttraumatic stress disorder. CNS Spectr. 2003 Aug; 8(8 Suppl 1):31-9.
Score: 0.014
-
WCA recommendations for the long-term treatment of social phobia. CNS Spectr. 2003 Aug; 8(8 Suppl 1):40-52.
Score: 0.014
-
WCA recommendations for the long-term treatment of generalized anxiety disorder. CNS Spectr. 2003 Aug; 8(8 Suppl 1):53-61.
Score: 0.014
-
Should the administration of ECT during clozapine therapy be contraindicated? Br J Psychiatry. 1996 Aug; 169(2):253-4.
Score: 0.008
-
Clinical issues in the long-term treatment of panic disorder. J Clin Psychiatry. 1996; 57 Suppl 10:44-8; discussion 49-50.
Score: 0.008
-
Integration of behavioral and pharmacological treatments for panic disorder: implications for the treatment of substance dependence. NIDA Res Monogr. 1995; 150:143-66.
Score: 0.007
-
Discontinuation of benzodiazepine treatment: efficacy of cognitive-behavioral therapy for patients with panic disorder. Am J Psychiatry. 1993 Oct; 150(10):1485-90.
Score: 0.007
-
Major depression in panic disorder patients with comorbid social phobia. J Affect Disord. 1991 Jul; 22(3):171-7.
Score: 0.006